Patient characteristics, treatment patterns, and survival across estrogen receptor expression subgroups in HER2-negative breast cancer: a population-based cohort study
In brief
Chemo plus endocrine therapy halves death risk in ER10-59% HER2-negative breast cancer
In a Swedish cohort of 75,000 HER2-negative patients, those with tumors expressing 10-59% estrogen receptor had 30-60% higher mortality than ER-high cancers, but receiving both chemotherapy and endocrine therapy cut their risk of death by roughly half compared with endocrine therapy alone. The results suggest that reporting ER as a percentage can guide more aggressive treatment for these intermediate-ER tumors.
- Journal
- The Lancet regional health. Europe (Q1)
- Published
- 26 August 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Qiao Yang, Ceren Boyaci, Ioannis Zerdes, Irma Fredriksson, Xinsong Chen, Johan Hartman, et al.
- PMID
- 42724667
- DOI
- 10.1016/j.lanepe.2026.101826
Why clinicians should know about it
- Picked for Epidemiology (paper of the day, 12 September 2026): Population cohort of ER subgroups in HER2‑negative breast cancer
Abstract
BACKGROUND: Estrogen receptor (ER) low (1-9%) breast cancer (BC) often behaves like triple-negative BC, while ERhigh (≥60%) disease has a more favorable prognosis. However, tumors with ER expressing 10-59% represent a poorly defined patient population. In this nationwide cohort study, we aimed to describe real-world patient characteristics, treatment patterns and survival across the entire ER spectrum in Human Epidermal growth factor Receptor 2 (HER2)-negative BC. METHODS: We conducted a population-based cohort study of all women diagnosed with HER2-negative BC in Sweden (2007-2023), based on prospectively collected data. Tumors were stratified into five ER subgroups: ER0% (ERzero), ER1-9% (ERlow), ER10-29% (ERmild), ER30-59% (ERmod), and ER60-100% (ERhigh). We evaluated overall survival (OS) by ER subgroups and treatment (chemotherapy [CT] and endocrine therapy [ET]) using Kaplan-Meier analysis and multivariable Cox regression. FINDINGS: We included 75,211 patients. Compared to the ERhigh subgroup, both the ERmild (adjusted HR [aHR] = 1.59, 95% confidence interval [CI]: 1.31-1.93) and ERmod (aHR = 1.31, 95% CI: 1.17-1.47) subgroups had significantly worse survival (both adjusted P [aP] < 0.001). Notably, ERmild patients had survival outcomes and molecular characteristics similar to those of ERlow and ERzero patients. Patients with ERmild (aHR = 0.46, 95% CI: 0.23-0.94, aP = 0.033) and ERmod (aHR = 0.60, 95% CI: 0.42-0.85, aP = 0.0046) tumors, CT + ET was associated with a lower risk of death than ETonly. INTERPRETATION: Our findings highlight the importance of assessment of ER-low, mild and moderate tumors (1-59%). Reporting ER as a percentage can provide additional biological insight in clinical decision-making. FUNDING: This study received no external funding.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.